Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26167764 | 0.95 | ALDH1A1 (0.36) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22327196 | 0.91 | ALDH1A1 (0.36) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25753752 | 0.90 | ALDH1A1 (0.36) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL26167941 | 0.89 | MAOB (0.41) | KMT2AALDH1A1SMN1; SMN2NR1H4MAOB | |
| SCHEMBL23106220 | 0.83 | ALDH1A1 (0.37) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL26010471 | 0.83 | ALDH1A1 (0.37) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25753973 | 0.83 | MAPT (0.35) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24002371 | 0.83 | ALDH1A1 (0.37) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL26167914 | 0.82 | HPGD (0.40) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL26319090 | 0.81 | MAOB (0.40) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230265505-A1 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-24 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230227798-A1 | MODIFIED THERMOCCOCUS POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-11697736-B2 | Silicon containing detectable compounds | Singular Genomics Systems, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230160001-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697736-B2 | Silicon containing detectable compounds | AS3MT, SCLY, NASP | GAA 251/4885MAPT 4045/4885KMT2A 3136/4885 |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | GAA 251/4885MAPT 4045/4885KMT2A 3136/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | GAA 1026/4885MAPT 4328/4885KMT2A 1334/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | GAA 1026/4885MAPT 4328/4885KMT2A 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.